Review
Current practice
Antiplatelet use in interventional cardiology
Adrian Brodisona, Ravish Katiraa, Ranjit S Moreb, Anoop Chauhana
a Regional
Cardiothoracic Centre, Blackpool Victoria Hospital, Whinney Heys Road,
Blackpool, Lancashire FY3 8NR, UK, b St Mary's Hospital,
Portsmouth, UK
Correspondence to: Dr A Chauhan
Submitted 18 February
1999;
Accepted 13 August 1999
Thrombosis within the target vessel is one of the most feared
complications associated with coronary intervention, as it is often
associated with severe adverse clinical sequelae. This thrombosis is
mediated via the activation and aggregation of platelets and therefore
considerable effort has been directed at ways of inhibiting platelet
function. It is now mandatory to consider the use of two and often
three different antiplatelet agents, particularly when intracoronary
stents are inserted. Using these regimes, many of the adverse clinical
outcomes associated with platelet activation can be reduced.
Keywords: platelets; cardiology; antiplatelet agents; glycoprotein receptor antagonists
© 2000 by The Fellowship of Postgraduate Medicine
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
